Synthesis and Investigation of Radiopharmaceutical Complexes Based on 177Lu and 212Pb for the Targeted Therapy of Malignant Neoplasms

O. L. Polyanovskii, E. N. Lebedenko, and S. M. Deev, “ERBB-oncogene—proteins as targets for monoclonal antibodies,” Biochemistry (Moscow) 77, 227 (2012).

S. M. Deev, E. N. Lebedenko, L. E. Petrovskaya, D. A. Dolgikh, A. G. Gabibov, and M. P. Kirpichnikov, “Man-made antibodies and immunoconjugates with desired properties: Function optimization using structural engineering,” Russ. Chem. Rev. 84, 1 (2015). https://doi.org/10.1070/RCR4459

O. N. Shilova and S. M. Deev, “DARPins: Promising scaffolds for theranostics,” Acta Natur. 11 (4), 42 (2019).

A. Orlova, M. Magnusson, T. L. Eriksson, et al., “Tumor imaging using a picomolar affinity HER2 binding affibody molecule,” Cancer Res. 66, 4339 (2006). https://doi.org/10.1158/0008-5472.CAN-05-3521

S. M. Deyev, A. Vorobyeva, A. Schulga, et al., “Comparative evaluation of two DARPin variants: Effect of affinity, size and label on tumor targeting properties,” Mol. Pharm. 16, 995 (2019). https://doi.org/10.1021/acs.molpharmaceut.8b00922

D. Pilati and K. A. Howard, “Albumin-based drug designs for pharmacokinetic modulation,” Expert Opin Drug Metab. Toxicol. 16, 783 (2020). https://doi.org/10.1080/17425255.2020.1801633

W. A. Volkert and T. J. Hoffman, “Therapeutic radiopharmaceuticals,” Chem. Rev. 99, 2269 (1999). https://doi.org/10.1021/cr9804386

A. Dash, M. R. A. Pillai, and F. F. Knapp, Jr., “Production of 177Lu for targeted radionuclide therapy: Available options,” Nucl. Med. Mol. Imaging 49, 85 (2015). https://doi.org/10.1007/s13139-014-0315-z

F.-M. Su, P. Beaumier, D. Axworthy, et al., “Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator,” Nucl. Med. Biol. 32, 741 (2005). https://doi.org/10.1016/j.nucmedbio.2005.06.009